# US 2025/0154264 A1 · Anti-alk1 antibodies and methods of using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154264 A1
- Document ID: US20250154264A1
- Status: Published application
- Kind: A1
- Application number: 18/832,414
- Filed: 2023-01-23
- Published: 2025-05-15
- Earliest claimed: 2022-01-24
- Assignees: Genovac Antibody Discovery LLC; Yale University
- Applicants: Genovac Antibody Discovery LLC; Yale University
- Inventors: Hubertus Schleer; William Sessa
- Web page: https://patentgrep.com/patent/US20250154264A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides antibodies that bind to ALK1 and methods/uses of the disclosed antibodies for treating various conditions (e.g., atherosclerosis). The present disclosure provides anti-ALK1 antibodies, comprising the complementarity determining regions (CDRs) of a heavy chain variable sequence and a light chain variable sequence selected from: the heavy chain variable sequence of SEQ ID NO: 2 and the light chain variable sequence of SEQ ID NO: 3. In some embodiments, the disclosed antibodies bind to human ALK1, murine ALK1, cynomolgus ALK1, or a combination thereof. The present disclosure also provides pharmaceutical compositions comprising an anti-ALK1 antibody accordingly to any one of the foregoing aspects or embodiments and a pharmaceutically acceptable carrier.

## Claims

### Claim 1

An anti-ALK1 antibody, comprising the complementarity determining regions (CDRs) of a heavy chain variable sequence and a light chain variable sequence selected from:
a. the heavy chain variable sequence of SEQ ID NO: 2 and the light chain variable sequence of SEQ ID NO: 3;
b. the heavy chain variable sequence of SEQ ID NO: 4 and the light chain variable sequence of SEQ ID NO: 5;
c. the heavy chain variable sequence of SEQ ID NO: 6 and the light chain variable sequence of SEQ ID NO: 7;
d. the heavy chain variable sequence of SEQ ID NO: 10 and the light chain variable sequence of SEQ ID NO: 11; and
e. the heavy chain variable sequence of SEQ ID NO: 12 and the light chain variable sequence of SEQ ID NO: 13.

### Claim 2 (depends on 1)

The anti-ALK1-antibody of claim 1, further comprising a variable heavy chain sequence and a variable light chain sequence selected from:
a. the heavy chain variable sequence of SEQ ID NO: 2 and the light chain variable sequence of SEQ ID NO: 3;
b. the heavy chain variable sequence of SEQ ID NO: 4 and the light chain variable sequence of SEQ ID NO: 5;
c. the heavy chain variable sequence of SEQ ID NO: 6 and the light chain variable sequence of SEQ ID NO: 7;
d. the heavy chain variable sequence of SEQ ID NO: 10 and the light chain variable sequence of SEQ ID NO: 11; and
e. the heavy chain variable sequence of SEQ ID NO: 12 and the light chain variable sequence of SEQ ID NO: 13.

### Claim 3 (depends on 1)

The anti-ALK1 antibody of claim 1, wherein the heavy chain variable sequence comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2, 4, 6, 10, or 12, and the light chain variable sequence comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 3, 5, 7, 11, or 13.

### Claim 4 (depends on 1)

The anti-ALK1 antibody of claim 1, wherein the heavy chain variable sequence comprises 1-10 amino acid substitutions, insertions or deletions in SEQ ID NO: 2, 4, 6, 10, or 12, and the light chain variable sequence comprises 1-10 amino acid substitutions, insertions or deletions in SEQ ID NO: 3, 5, 7, 11, or 13.

### Claim 5

An anti-ALK1 antibody comprising a heavy chain comprising a CDRH1 comprising SSYWN (SEQ ID NO: 26), a CDRH2 comprising EVNHSGSTNYNPSLKS (SEQ ID NO: 27), and a CDRH3 comprising SPRSGRIVGAVFDY (SEQ ID NO: 28); and a light chain comprising a CDRL1 comprising GGNNIGPKSVH (SEQ ID NO: 29), a CDRL2 comprising DDSDRPS (SEQ ID NO: 30), and a CDRL2 comprising QVWDSSNDHVV (SEQ ID NO: 31).

### Claim 6

An anti-ALK1 antibody comprising a heavy chain comprising a CDRH1 comprising SRSYYWG (SEQ ID NO: 32), a CDRH2 comprising NIYYSGSAFYNPSLKS (SEQ ID NO: 33), and a CDRH3 comprising WDNWDVGAFDI (SEQ ID NO: 34); and a light chain comprising a CDRL1 comprising TGTSSDVGGYNYVS (SEQ ID NO: 35), a CDRL2 comprising EVSKRPS (SEQ ID NO: 36), and a CDRL2 comprising TSFAGSNNWV (SEQ ID NO: 37).

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A method of treating or preventing a disease or disorder associated with ALK1, comprising administering to a subject with a disease or disorder associated with ALK1 an antibody of any one of claims 1-6.

### Claim 8 (depends on 7)

The method of claim 7, wherein the disease is atherosclerosis.

### Claim 9 (depends on 7, 8)

The method of claim 7 or 8, wherein the subject is human.
